Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Restructuring Costs (2023)

Rein Therapeutics filings provide 1 years of Restructuring Costs readings, the most recent being -$12000.0 for Q4 2023.

  • For the quarter ending Q4 2023, Restructuring Costs changed N/A year-over-year to -$12000.0, compared with a TTM value of -$12000.0 through Sep 2024, changed N/A, and an annual FY2023 reading of $928000.0, changed N/A over the prior year.
  • Restructuring Costs hit -$12000.0 in Q4 2023 for Rein Therapeutics, down from $6000.0 in the prior quarter.
  • The five-year high for Restructuring Costs was $1.0 million in Q1 2023, with the low at -$88000.0 in Q2 2023.